What does BIOCLIN do?

BIOCLIN is a logistics company in Oostende. Public Limited, started on 30 October 1976, 1 establishment.

What is the address of BIOCLIN?

The registered office of BIOCLIN is located at Troonstraat 60, 8400 Oostende.

Is BIOCLIN still active?

Yes. According to the CBE (29 October 2026) BIOCLIN is active, legal situation “Normale toestand”, started on 30 October 1976.

Is BIOCLIN registered on Peppol?

Yes, BIOCLIN is registered on the Peppol network with ID 0208:0416553335.

What is the enterprise number of BIOCLIN?

The enterprise number of BIOCLIN is BE0416553335.

When was BIOCLIN founded?

BIOCLIN was founded on 30 October 1976.

Who are the directors of BIOCLIN?

According to the 2025 annual accounts, the directors of BIOCLIN are: Lien MATTON, Camba-Pharma BV, LITHIPHARMA NV.

Is BIOCLIN a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 30 October 1976; 5 annual accounts filed, latest fiscal year 2025; 3 directors known from the annual account.

How much profit did BIOCLIN make in 2025?

BIOCLIN posted a profit after taxes of € 8,400 in financial year 2025.

What is the revenue of BIOCLIN?

As a small company, BIOCLIN is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 97,820.

How many employees does BIOCLIN have?

According to the 2025 annual accounts, BIOCLIN has 0.5 full-time equivalents (FTE).

BIOCLIN (Public Limited) - Oostende - BE0416553335

Dossier BIOCLIN, printed on 29 October 2026 from databakkes.be/en/0416553335/bioclin. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

BIOCLIN from Oostende, company number BE0416553335, closed financial year 2025 with a result of € 8,400 after tax. For that financial year BIOCLIN recorded a gross margin of € 97,820 and equity of € 274,684. Compared with financial year 2024, the result moved from € 28,717 to € 8,400. The company is profitable. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 19, 2026.

What it is worth Healthy

€ 274,684

▼ 3% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 8,400

▼ 71% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 39,539

▼ 13% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 16,000 paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2025

Full-time equivalents

0.5

▲ 0.1 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 38,768

▲ 13% vs 2024

Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 3,421

▲ 173% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 8 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 138,754

▼ 5% vs 2024

€ 16,349 is repaid this year. At this pace the long-term loan is gone in ≈ 8 years.

Owed to suppliers

€ 124,862

▲ 15% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 6,963

▲ 36% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 114,871 Gross margin 2022: € 114,871 First fiscal year in the series	€ 53,883 Gross margin 2023: € 53,883 ▼ 53% vs 2022 (€ 114,871) Unfavourable step	€ 100,319 Gross margin 2024: € 100,319 ▲ 86% vs 2023 (€ 53,883) Favourable step	€ 97,820 Gross margin 2025: € 97,820 ▼ 2% vs 2024 (€ 100,319) Unfavourable step	▼ 2%
Profit after taxes	€ 55,877 Profit after taxes 2022: € 55,877 First fiscal year in the series	€ 139,657 Profit after taxes 2023: € 139,657 ▲ 150% vs 2022 (€ 55,877) Favourable step	€ 28,717 Profit after taxes 2024: € 28,717 ▼ 79% vs 2023 (€ 139,657) Unfavourable step	€ 8,400 Profit after taxes 2025: € 8,400 ▼ 71% vs 2024 (€ 28,717) Unfavourable step	▼ 71%
Equity	€ 147,409 Equity 2022: € 147,409 First fiscal year in the series	€ 287,066 Equity 2023: € 287,066 ▲ 95% vs 2022 (€ 147,409) Favourable step	€ 282,283 Equity 2024: € 282,283 ▼ 2% vs 2023 (€ 287,066) Unfavourable step	€ 274,684 Equity 2025: € 274,684 ▼ 3% vs 2024 (€ 282,283) Unfavourable step	▼ 3%
Total debts	€ 545,137 Total debts 2022: € 545,137 First fiscal year in the series	€ 275,594 Total debts 2023: € 275,594 ▼ 49% vs 2022 (€ 545,137) Favourable step	€ 335,495 Total debts 2024: € 335,495 ▲ 22% vs 2023 (€ 275,594) Unfavourable step	€ 314,432 Total debts 2025: € 314,432 ▼ 6% vs 2024 (€ 335,495) Favourable step	▼ 6%
Cash	€ 32,806 Cash 2022: € 32,806 First fiscal year in the series	€ 16,578 Cash 2023: € 16,578 ▼ 49% vs 2022 (€ 32,806) Unfavourable step	€ 45,395 Cash 2024: € 45,395 ▲ 174% vs 2023 (€ 16,578) Favourable step	€ 39,539 Cash 2025: € 39,539 ▼ 13% vs 2024 (€ 45,395) Unfavourable step	▼ 13%
Land & buildings	€ 25,060 Land & buildings 2022: € 25,060 First fiscal year in the series	-	-	-
Retained profit	€ 84,858 Retained profit 2022: € 84,858 First fiscal year in the series	€ 224,514 Retained profit 2023: € 224,514 ▲ 165% vs 2022 (€ 84,858) Favourable step	€ 220,283 Retained profit 2024: € 220,283 ▼ 2% vs 2023 (€ 224,514) Unfavourable step	€ 212,684 Retained profit 2025: € 212,684 ▼ 3% vs 2024 (€ 220,283) Unfavourable step	▼ 3%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 0 Dividend 2023: € 0 Unchanged (€ 0) Unchanged	€ 33,500 Dividend 2024: € 33,500 Unchanged (€ 0) Unchanged	€ 16,000 Dividend 2025: € 16,000 ▼ 52% vs 2024 (€ 33,500) Unchanged	▼ 52%
Bank debt	€ 2,857 Bank debt 2022: € 2,857 First fiscal year in the series	€ 0 Bank debt 2023: € 0 ▼ 100% vs 2022 (€ 2,857) Favourable step	€ 145,894 Bank debt 2024: € 145,894 Unchanged (€ 0) Unfavourable step	€ 138,754 Bank debt 2025: € 138,754 ▼ 5% vs 2024 (€ 145,894) Favourable step	▼ 5%
Balance sheet total	€ 692,547 Balance sheet total 2022: € 692,547 First fiscal year in the series	€ 607,225 Balance sheet total 2023: € 607,225 ▼ 12% vs 2022 (€ 692,547) Unchanged	€ 657,219 Balance sheet total 2024: € 657,219 ▲ 8% vs 2023 (€ 607,225) Unchanged	€ 623,434 Balance sheet total 2025: € 623,434 ▼ 5% vs 2024 (€ 657,219) Unchanged	▼ 5%
Employees (FTE)	0.6 Employees (FTE) 2022: 0.6 First fiscal year in the series	0.4 Employees (FTE) 2023: 0.4 ▼ 0.2 vs 2022 (0.6) Unchanged	0.4 Employees (FTE) 2024: 0.4 Unchanged (0.4) Unchanged	0.5 Employees (FTE) 2025: 0.5 ▲ 0.1 vs 2024 (0.4) Unchanged	▲ 0.1

Key figures of BIOCLIN, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to BIOCLIN?

What happened at BIOCLIN in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2032 Camba-Pharma BV stepped down as director. NBB
Jun 19, 2026 New annual accounts for financial year 2025: profit of € 8,400 (▼ 71% vs 2024). Source: NBB ↗
2026 Lien MATTON stepped down as director. NBB
2026 Camba-Pharma BV became a director. NBB
2026 LITHIPHARMA NV stepped down as director. NBB
2020 Lien MATTON became a director. NBB
2020 LITHIPHARMA NV became a director. NBB
Feb 1, 1980 New establishment in Oostende. KBO

In short

From € 55,877 profit in 2022 to € 8,400 profit in 2025.

Paid € 10,132 in corporate taxes since 2022.

Best year ever: 2023, with € 139,657 profit.

Paid out € 49,500 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Camba-Pharma 50%

LITHI - PHARMA 49.8%

The stake of Camba-Pharma, LITHI - PHARMA comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

BIOCLIN

Thuiszorg Coöperatie 0%

The shares are held by Camba-Pharma (50%) and LITHI - PHARMA (49.8%). It owns 0% of Thuiszorg Coöperatie itself.

Directors

According to the 2025 annual accounts

Lien MATTON

Director

since 2020 · until 2026

Camba-Pharma BV

Director · represented by Camille Baetslé

since 2026 · until 2032

LITHIPHARMA NV

Managing director · represented by Thierry Baetslé

since 2020 · until 2026

Shareholders

Camba-Pharma

50%

LITHI - PHARMA

49.8%

Participations

Thuiszorg Coöperatie

Establishments

Establishment units

Physical locations of this company

Registered office

Troonstraat 60

8400 Oostende

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

Vereniging van Mede-eigenaars Residentie Hof Ter Zee te Oostende, Troonstraat 60

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0416.553.335

VAT number

BE 0416.553.335

Registered office

Troonstraat 60, 8400 Oostende

Names & denominations

BIOCLIN

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

30 October 1976

Peppol

Active · Active since 24 Nov 2023

Activities · NACE

Apothekers

Detailhandel in farmaceutische producten

View on CBE Public ↗ Annual accounts (NBB) ↗

BIOCLIN

Financials

What happened to BIOCLIN?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions